Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor

NCT07472322 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT07472322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07472322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
May 31, 2031
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma, merkel cell carcinoma, stage iii, merkel cell carcinoma, stage iv